Latest Patent Litigation News

Page 1 of 2
Moderna’s chief legal officer will retire in March under an agreement that provides US$1.63 million in fixed severance and up to US$8 million linked to litigation outcomes. The package also preserves her salary, benefits and equity vesting through her departure date.
Ada Torres
Ada Torres
14 Nov 2026
Mayne Pharma has settled its final US Paragraph IV patent dispute over IMVEXXY with Teva, setting a potential generic entry date of 2 September 2032. The agreement removes ongoing litigation without an upfront payment, while leaving court approval and earlier-entry provisions to resolve.
Victor Sage
Victor Sage
16 Oct 2026
Mayne Pharma has settled patent litigation with Sun Pharma over IMVEXXY, establishing 21 October 2032 as the agreed potential generic entry date, subject to court approval. The settlement involves no upfront payment, while one further Paragraph IV dispute remains unresolved.
Victor Sage
Victor Sage
30 Sept 2026
ResMed Inc. posted a 10% rise in fiscal 2026 revenue to $5.65 billion, bolstered by the acquisition of Noctrix Health and an agreement to sell its MatrixCare business. The company continues to invest in AI-powered digital health solutions amid ongoing patent litigation and a shifting regulatory landscape.
Ada Torres
Ada Torres
14 Aug 2026
Identitii is contesting JPMorgan Chase’s motion seeking a $4 million attorneys’ fee award in their ongoing US patent dispute, while continuing its appeal against case dismissal.
Sophie Babbage
Sophie Babbage
23 June 2026
A US court has dismissed Identitii's patent infringement claim against JPMorgan Chase, citing patent ineligibility. Identitii plans to appeal, while its core business remains unaffected.
Sophie Babbage
Sophie Babbage
1 June 2026
EROAD reported flat group revenue of NZD 195.2 million for FY26, driven by strong Australian growth and steady New Zealand performance, offset by a North American decline and a hefty goodwill impairment.
Sophie Babbage
Sophie Babbage
25 May 2026
Resmed delivered a robust Q3 FY2026 with 11% revenue growth, margin expansion, and a 21% jump in non-GAAP EPS, while announcing a new U.S. distribution centre and a $0.60 dividend.
Ada Torres
Ada Torres
1 May 2026
Acusensus Limited has settled its patent litigation with Redflex Traffic Systems, issuing over six million shares and paying US$6 million in cash to resolve the dispute. The agreement clears the way for Acusensus to continue its road safety technology operations unimpeded.
Sophie Babbage
Sophie Babbage
6 Feb 2026
ResMed Inc. reported robust financial results for Q2 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. The company also navigates ongoing patent litigation while maintaining solid liquidity and shareholder returns.
Ada Torres
Ada Torres
2 Feb 2026
Identitii Limited has announced a pro rata non-renounceable rights issue to raise approximately $2.88 million, partially underwritten by Beauvais Capital Pty Ltd. The funds will support the development and commercialisation of its BNDRY platform amid ongoing patent litigation risks.
Sophie Babbage
Sophie Babbage
4 Dec 2025
ResMed Inc. reported a robust 9% increase in net revenue for Q1 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. Despite ongoing patent litigation, the company delivered a 12% rise in net income and boosted shareholder returns with a $150 million share repurchase.
Ada Torres
Ada Torres
3 Nov 2025

Browse the archive

Full archive